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Abstract
Background:  It has been demonstrated that extracellular mRNA can be detected in the
circulation. Our hypothesis was that circulating miRNAs are also present and differentially
expressed in the serum of breast cancer patients compared to controls.
Findings: We measured miRNA in the serum of samples with and without the addition of miRNA
prior to analysis. To test our RNA extraction efficiency, we spiked-in serial dilutions of single-
strand C elegens miR-39 (cel-miR-39) and human miR-145 (has-miR-145) into goat serum and a 10
year old human serum specimen. We next analyzed miR-16, -145, and -155 in archived serum
specimens from 21 participants, 13 of whom did and 8 of whom did not have breast cancer. We
were able to detect the miRNAs from all the serum samples to which the miRNAs had been added.
We were also able to detect endogenous miR-16, -145, and -155 in all serum samples. While the
expression of all three miRNAs was similar in samples from healthy women compared to those
with breast cancer, women with progesterone receptor (PR, p = 0.016) positive tumors had higher
miR-155 expression than tumors that were negative for these receptors.
Conclusion: 1) RNA species can be detected in archived serum; 2) miR-155 may be differentially
expressed in the serum of women with hormone sensitive compared to women with hormone
insensitive breast cancer. Screening serum for miRNAs that predict the presence of breast cancer
is feasible, and may be useful for breast cancer detection.
Background and research hypothesis
There is increasing evidence supporting microRNA
(miRNA) analysis for breast cancer diagnosis, prognosis
and therapy [1-3]. miRNAs are ~22 nucleotide long RNA
molecules encoded in the genome that can control gene
expression. Their expression levels vary greatly among
species and tissues [4]. Over 700 miRNAs have been iden-
tified from human tissue. Some of these short, endog-
enous non-protein coding miRNAs are linked to human
malignancy and are differentially expressed in human
cancer vs. matched normal tissue [5]. For example, a
recent publication identified 29 miRNAs that were aber-
rantly expressed in primary breast cancer tissue. Of the 29,
miR-10b, miR-125b, and miR-145 were down-regulated,
while miR-21 and miR-155 were up-regulated [6].
Depending on the genes that the miRNAs act on, they may
serve to stimulate or suppress tumor formation and
growth. Another team reported 15 miRNAs that are
expressed in a variety of normal human tissues. Among
them, miR-16 is expressed at a higher level than the
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remaining 14 miRNAs [7]. These differences provide the
molecular basis and rationale for the identification of
miRNAs in breast cancer detection.
Cancer-related RNAs are present and detectable in serum
[8-11], and it was recently reported that the levels of cyclin
D1 and thymidylate synthase levels of free mRNA in
plasma correlated with nonresponse to breast cancer ther-
apy [12]. As RNase is present in the blood of healthy and
cancer containing individuals [13], one would expect all
circulating RNA (including miRNAs) in the blood to be
rapidly destroyed. However, accumulated data suggest
that circulating RNA may not be as fragile as was previ-
ously assumed. Tsui et al. reported that RNA in serum is
more RNase resistant and stable than previously thought
[14]. For example, tyrosinase mRNA has been found in
the serum of melanoma patients but not in healthy indi-
viduals [9], and epithelial mRNA in the plasma of breast
cancer patients was associated with poor prognosis [15].
Both observations demonstrate that cancer-related mRNA
exists in the circulation and is detectable. Finally, a recent
pilot study demonstrated that miRNAs can be detected in
the serum of ovarian cancer patients [16]. Our hypothesis
was that circulating miRNAs are also present and detecta-
ble in the serum of breast cancer patients.
Methods
Blood Collection and serum preparation
After informed consent was obtained from 21 participants
(13 with breast cancer and 8 normal controls, Table 1), 6
ml of venous blood was collected from the antecubital
fossa and placed in a serum separator tube. The blood was
centrifuged at 1600 rpm for 5 min and the serum aliq-
uoted into 1.7 ml Eppendorf tubes, followed by a 15 min
high speed centrifugation at 12,000 rpm to completely
remove cell debris, leaving only circulating RNA. To test
our RNA extraction efficiency while minimizing possible
interference from endogenous RNA, we used a 10 year old
human serum sample and goat serum, to which cel-miR-
39 and has-miR-145 were concurrently spiked in.
RNA Extraction
We first evaluated our RNA extraction efficiency. Either
105, 103, 10, 10-1, or 0 pg of single stranded cel-miR-39
and has-miR-145 synthesized by Invitrogen (Carlsbad, CA
92008) were spiked into 400 μL of both goat serum
(Abcam, Cambridge, MA) and 10 year old archived
human serum collected from a single subject. We isolated
total RNA which included miRNA in 400 μL of serum
from 21 participants using the MagMAX™Viral RNA Isola-
tion kit following the manufacturer's instructions
(Ambion, Austin, TX). The RNA was stored at -80°C until
use. Both MagMAX™Viral RNA Isolation kit and mirVana
paris kit ™ have been recommended to isolate small RNAs
in serum by the supplier. We chose the MagMAX kit
because it provided better miRNA recovery from the
serum samples. We were able to increase our miRNA
recovery by 1) extending the incubation and binding time
from four to 10 minutes, and 2) increasing the ratio of iso-
propanol to wash buffer # 1 in the kit from 1:2 to 1:1.
Different quantities (105, 103, 10, 10-1, and 0 pg) of cel-miR- 39 (blue curves) and has-miR-145 (red curves) inputs led to  similar corresponding Ct values of 19.2, 25.8, 32.4, 37.10 and  undetectable, respectively Figure 1
Different quantities (105, 103, 10, 10-1, and 0 pg) of 
cel-miR-39 (blue curves) and has-miR-145 (red 
curves) inputs led to similar corresponding Ct values 
of 19.2, 25.8, 32.4, 37.10 and undetectable, respec-
tively.
Table 1: Demographics of Participant Samples
Yes No Unknown
Breast Cancer 13 8
Disease Stage
14
25
34
Estrogen receptor positive 10 2 1
Progesterone receptor positive 93 1
HER2/neu positive 11 1 1
Race
Caucasian 19
African American 2BMC Research Notes 2009, 2:89 http://www.biomedcentral.com/1756-0500/2/89
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Reverse Transcription (RT) and Quantitative PCR (qPCR)
RT and qPCR kits made specifically for accurate miRNA
analysis (Applied Biosystems) were used to evaluate
expression of the following miRNAs from serum samples:
cel-miR-39, has-miR-16, miR-145 and miR-155. 18s rRNA
was used to normalize the RNA input. The RT reaction for
18s rRNA was performed with RETROscrit® Kit (Ambion,
catalog # AM1710). An equal volume of the eluted RNA
(5 μL/reaction = 1/10 of the eluted volume) was reverse-
transcribed with specific looped RT primers for each
miRNA evaluated. The 15 μL RT reactions were performed
using a TaqMan®  microRNA Reverse Transcription Kit
(Applied Biosystems catalog # 4366596) and incubated
for 30 min at 16°C, 30 min at 42°C, 5 min at 85°C, and
then maintained at 4°C. For real-time PCR, 5 μL RT prod-
ucts were used as templates in 20 μL reactions containing
primers and probes for each miRNA and 18s rRNA accord-
ing to manufacturer instructions. All reactions were run
on the MyiQ™ Real-Time PCR Detection System (Bio-Rad,
Hercules, CA) using the following conditions: 95°C for
10 min, followed by 40 cycles at 95°C for 15 s, and 60°C
for 1 min. The relative miRNA quantity in serum from
participants with vs. without breast cancer was deter-
mined using the comparative Ct method (Bulletin #2: ABI
Prism 7700 Sequence Detection System, Applied Biosys-
tems, 1997).
Results and discussion
Early detection is a major factor contributing to the 2.3%
annual decline in breast cancer death rates over the past
10 years [17]. Nonetheless 40,480 women in the U.S.
were projected to die from breast cancer in 2008 [18], in
part because currently available breast cancer screening
tools such as mammography and breast examination miss
10–40% of early breast cancers and are least effective in
detecting cancer in young women, whose tumors are often
more aggressive. An invasive needle or surgical biopsy
must be performed when an area of suspicion is identified
in order to confirm, by cytologic or histologic evaluation,
the presence of malignancy, even though 66–85% of
abnormalities are benign [19].
In principle, there are three different ways in which
biomarkers can be used. First, they can be used to differ-
entiate normal from diseased states. Second, they can be
used to determine into which prognostic groups subjects
should be placed. Finally, biomarkers can be used to mon-
itor response to therapy. The identification of biologic
markers such as miRNA species collected noninvasively in
the circulation that would distinguish between women
with or without breast cancer is therefore of crucial impor-
tance in early cancer detection, to improve disease free
and overall survival from the disease. There is a recent
report which outlines the usefulness of miRNA signatures
to distinguish normal from diseased tissues and tissue ori-
gin, relying upon miRNA signatures from formalin fixed,
paraffin embedded and frozen tissue specimens [20],
demonstrating the stability of miRNAs. Our miRNA find-
ings in archival serum support and extend these findings,
with the potential that miRNA analysis may prove useful
for noninvasive breast cancer detection.
We first tested if spiked-in cel-miR-39 and has-miR-145
were detectable in a 10 year old human serum and a goat
serum specimen. The specimen was divided into five sam-
The Ct value for endogenous GAPDH mRNA in each of the  serial human serum samples to which miR-145 was spiked in  was approximately 35 Figure 3
The Ct value for endogenous GAPDH mRNA in each 
of the serial human serum samples to which miR-145 
was spiked in was approximately 35.
There was linear recovery (slope = -3.0) of the miR-39 and  miR-145 at concentrations equal to and greater than 10-1pg/ 400 μL serum Figure 2
There was linear recovery (slope = -3.0) of the miR-
39 and miR-145 at concentrations equal to and 
greater than 10-1pg/400 μL serum.BMC Research Notes 2009, 2:89 http://www.biomedcentral.com/1756-0500/2/89
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ples of equal volume. Decreasing inputs of single-strand
cel-miR-39 and has-miR-145 (105, 103, 10, 10-1 and 0 pg)
added to each sample (Figures 1 and 2) led to the corre-
sponding mean Ct values (19.2, 25.8, 32.4, 37.1 and
38.7), respectively, with similar values for cel-39 and has-
145. The Ct value of 37.1 obtained using the most dilute
sample (10-1 pg) was slightly lower than background of
38.7, indicating that the level of endogenous miR-145 in
the human serum to which the synthetic single stranded
miR-145 mimic was spiked in was very low, and therefore
unlikely to have influenced the amplification of the syn-
thesized miR-145. The equidistant curves down to a con-
centration of 10-1pg/400 μL serum suggest linear recovery
(Figure 1) and efficient amplification (Figure 2, slope = -
3.0) of the added miRNAs. The Ct values (Figure 3) for
endogenous GAPDH mRNA in the serial serum samples
to which has-miR-145 was spiked in were approximately
35. The results demonstrate that circulating RNA, includ-
ing endogenous GAPDH mRNA and spiked-in cel-miR-39
and has-miR-145, can be efficiently extracted and ampli-
fied from serum.
We then performed a pilot study in serum specimens from
21 women with and without breast cancer (Table 2) to
assess the expression of miR-16, -145 and -155 using 18s
rRNA to normalize the relative expression of the miRNAs
in archived serum specimens from women with and with-
out breast cancer. Each miRNA and 18s rRNA was isolated
and amplified efficiently in all subjects. The expression of
all three miRNAs in serum was similar in samples from
healthy women compared to those with breast cancer,
unlike a prior report which found differences in the
expression of mi-R-145 and -155 miRNAs in breast cancer
tissue vs. benign tissue women [6]. On the other hand,
progesterone receptor (PR, p = 0.016) positive tumors had
higher miR-155 expression than tumors that were nega-
tive for this receptor. miR-155 has been classified as a
multifunctional miRNA, having an important role in both
normal and pathologic processes in immunity, inflamma-
tion, cancer and cardiovascular disease [21]. The signifi-
cance of our finding regarding miR-155 and the PR will
require a larger study.
In determining the proper endogenous control for qPCR,
we initially tried three small non-coding nucleoar RNAs
(Rnu44, Rnu48 and Rnu66). Unfortunately, none were
useful because we could not detect them. GAPDH was
also tested but relatively high Ct values were observed, so
18s rRNA was tried levels adequate to serve as a control in
all human serum samples. We confirmed that our tech-
niques yielded adequate RNA extraction efficiency by
measuring levels of spiked-in cel-miR-39 and has-miR-
145. The spiked-in miRNAs had the advantage of lacking
homology to and thereby interference from endogenous
human miRNAs.
Conclusion
The efficient extraction and accurate identification of miR-
NAs from serum represents a key first step toward the
development of a noninvasive, blood-based detection test
for breast cancer, and we believe represents an important
advancement in achieving this goal.
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Table 2: The Ct Value of miR-16, miR-145 and miR155 in the Serum Samples with and without Breast Cancer
Ct value miR-16 miR-145 miR-155
NL1 TU1 NL TU NL TU
Range 21.57–25.55 21.76–26.14 32.96–36.50 32.62–37.60 33.95–35.84 31.88–38.94
Average 23.75 24.23 34.90 35.51 34.87 34.98
Median 23.79 24.46 34.97 35.35 34.93 34.90
T-test 0.49 0.35 0.87
1: NL = Normal serum, TU = Tumor serum. 21 serum samples (13 from subjects with breast cancer and eight controls). 18s rRNA was used to 
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